Decellularized Tissue-Specific ECM Substrates for Metastatic Cancer Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro metastasis models lack physiological relevance due to the inability to accurately recapitulate the metastatic niche environment, leading to misleading results in pre-clinical evaluations, as they often use synthetic biomaterials or non-equivalent substrates like Matrigel instead of tissue-specific extracellular matrix (ECM).
Innovation Solution
A cell culture platform comprising compartmentalized vessels with substrates made from decellularized tissue-specific extracellular matrix (TS-ECM) derived from different anatomical regions, providing a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycans to emulate the native ECM environment, allowing for the culture and assessment of cancer cells in a physiologically relevant manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If synthetic biomaterials or non-equivalent substrates like Matrigel are used, then the in vitro model can be manufactured and maintained, but the physiological relevance and accuracy of the model deteriorates
Solution Approach 1:
The patent extracts and isolates tissue-specific extracellular matrix components from native tissues through decellularization processes. This extraction allows the essential physiological features of the native ECM to be separated from cellular contaminants, creating a purified substrate that maintains biological authenticity while enabling controlled in vitro experimentation.
Solution Approach 2:
The patent modifies and characterizes the extracted ECM substrates by controlling parameters such as composition, structure, and biochemical properties. By adjusting these parameters, the substrates can be optimized to specific tissue types while maintaining their native physiological characteristics, thus improving model accuracy without sacrificing manufacturability.
2Measurement precision
If tissue-specific extracellular matrix is used, then the physiological relevance and accuracy of the model improves, but the complexity of obtaining and processing the material increases
Solution Approach 1:
The patent segments the complex process of obtaining tissue-specific ECM into distinct operational steps: tissue acquisition, decellularization, extraction, purification, and substrate formation. This segmentation allows each step to be optimized independently and facilitates standardized protocols that reduce overall complexity while maintaining physiological relevance.
Solution Approach 2:
The patent employs intermediary substances and reagents during the decellularization and extraction processes to facilitate the separation of ECM components from cellular elements. These intermediaries enable the efficient isolation of pure ECM substrates without requiring complex direct manipulation of the original tissue, thereby reducing processing complexity.
3Ease of operation
If conventional substrates are used, then the experimental setup is simple, but the translatability of results to clinical settings deteriorates
Solution Approach 1:
The patent creates in vitro models that copy the essential structural and biochemical features of native tissue-specific ECM. By replicating the authentic ECM environment, the models produce results that faithfully mirror in vivo biological behavior, thereby enhancing translatability while remaining experimentally manageable through standardized culture techniques.
Data Source
AI summary
A cell culture platform for modeling metastatic cancer is disclosed. The platform comprises one or more cell culture vessels comprising a plurality of compartments. Each compartment houses a substrate include a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. Each tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. A kit for culturing cells in biomimetic environments is also disclosed. The kit comprises a plurality of substrate precursors and at least one reagent. Each substrate precursor comprises a decellularized tissue-specific extracellular matrix derived from tissue of a different anatomical region. The tissue-specific extracellular matrix comprises a homogenous mixture of macromolecule fragments including collagen, elastin, and glycosaminoglycan. The reagent is configured to configured to convert each substrate precursor into a substrate adapted for culturing cells thereon. Methods of assessing a tumor-associated response of a cancer colony are also disclosed herein.